{"fetched":"2026-10-22","source":"https://api.openalex.org/works","license":"CC0","papers":{"paper-alsympca-radium-223-nejm-2013":{"doi":"10.1056/nejmoa1213755","openalexId":"W2141454098","cited":3408,"byYear":{"2012":4,"2013":50,"2014":250,"2015":253,"2016":288,"2017":279,"2018":321,"2019":268,"2020":274,"2021":307,"2022":253,"2023":252,"2024":230,"2025":213,"2026":155},"year":2013,"title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer"},"paper-netter-1-nejm-2017":{"doi":"10.1056/nejmoa1607427","openalexId":"W2573369749","cited":3298,"byYear":{"2012":1,"2014":1,"2016":1,"2017":144,"2018":254,"2019":277,"2020":355,"2021":427,"2022":364,"2023":350,"2024":390,"2025":369,"2026":354},"year":2017,"title":"Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors"},"paper-vision-nejm-2021":{"doi":"10.1056/nejmoa2107322","openalexId":"W3176208875","cited":2837,"byYear":{"2012":1,"2014":1,"2021":105,"2022":379,"2023":506,"2024":571,"2025":613,"2026":660},"year":2021,"title":"Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer"},"paper-propsma-hofman-lancet-2020":{"doi":"10.1016/s0140-6736(20)30314-7","openalexId":"W3012827461","cited":2046,"byYear":{"2012":1,"2013":1,"2019":1,"2020":128,"2021":300,"2022":337,"2023":324,"2024":317,"2025":359,"2026":273},"year":2020,"title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study"},"paper-clarinet-lanreotide-nejm-2014":{"doi":"10.1056/nejmoa1316158","openalexId":"W2135049144","cited":1942,"byYear":{"2013":1,"2014":35,"2015":119,"2016":151,"2017":186,"2018":163,"2019":166,"2020":168,"2021":195,"2022":175,"2023":158,"2024":174,"2025":143,"2026":96},"year":2014,"title":"Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors"},"paper-hofman-lupsma-lancet-oncol-2018":{"doi":"10.1016/s1470-2045(18)30198-0","openalexId":"W2799931007","cited":1177,"byYear":{"2017":1,"2018":47,"2019":124,"2020":169,"2021":234,"2022":145,"2023":132,"2024":125,"2025":117,"2026":82},"year":2018,"title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study"},"paper-therap-lancet-2021":{"doi":"10.1016/s0140-6736(21)00237-3","openalexId":"W3130934287","cited":1157,"byYear":{"2021":126,"2022":193,"2023":212,"2024":202,"2025":226,"2026":197},"year":2021,"title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial"},"paper-kratochwil-ac225-psma-jnm-2016":{"doi":"10.2967/jnumed.116.178673","openalexId":"W2467018059","cited":1103,"byYear":{"2015":1,"2016":8,"2017":52,"2018":85,"2019":84,"2020":126,"2021":139,"2022":115,"2023":110,"2024":143,"2025":143,"2026":97},"year":2016,"title":"225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer"},"paper-sgouros-tat-review-nat-rev-2020":{"doi":"10.1038/s41573-020-0073-9","openalexId":"W3045665740","cited":970,"byYear":{"2014":1,"2020":7,"2021":92,"2022":108,"2023":159,"2024":218,"2025":222,"2026":163},"year":2020,"title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges"},"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016":{"doi":"10.1056/nejmoa1510093","openalexId":"W2469052042","cited":818,"byYear":{"2014":3,"2016":19,"2017":81,"2018":87,"2019":81,"2020":102,"2021":102,"2022":94,"2023":74,"2024":67,"2025":52,"2026":53},"year":2016,"title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma"},"paper-detect-a-science-2020":{"doi":"10.1126/science.abb9601","openalexId":"W3020301997","cited":658,"byYear":{"2020":45,"2021":102,"2022":124,"2023":105,"2024":97,"2025":113,"2026":71},"year":2020,"title":"Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention"},"paper-sempet-de-santis-jco-2004":{"doi":"10.1200/jco.2004.07.188","openalexId":"W2151775324","cited":426,"byYear":{"2012":24,"2013":19,"2014":26,"2015":22,"2016":15,"2017":11,"2018":28,"2019":19,"2020":18,"2021":9,"2022":25,"2023":9,"2024":13,"2025":11,"2026":5},"year":2004,"title":"2- 18 fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial"},"paper-strosberg-netter1-qol-jco-2018":{"doi":"10.1200/jco.2018.78.5865","openalexId":"W2805387445","cited":392,"byYear":{"2014":1,"2017":1,"2018":10,"2019":44,"2020":57,"2021":63,"2022":63,"2023":45,"2024":47,"2025":39,"2026":20},"year":2018,"title":"Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177 Lu-Dotatate in the Phase III NETTER-1 Trial"},"paper-netter-2-lancet-2024":{"doi":"10.1016/s0140-6736(24)00701-3","openalexId":"W4399369977","cited":392,"byYear":{"2024":44,"2025":186,"2026":162},"year":2024,"title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study"},"paper-psmafore-lancet-2024":{"doi":"10.1016/s0140-6736(24)01653-2","openalexId":"W4402552580","cited":350,"byYear":{"2024":8,"2025":150,"2026":192},"year":2024,"title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial"},"paper-herrmann-radiotheranostics-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(19)30821-6","openalexId":"W3009386304","cited":327,"byYear":{"2020":17,"2021":34,"2022":44,"2023":58,"2024":50,"2025":65,"2026":59},"year":2020,"title":"Radiotheranostics: a roadmap for future development"},"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019":{"doi":"10.2967/jnumed.118.217463","openalexId":"W2895476867","cited":302,"byYear":{"2018":1,"2019":16,"2020":35,"2021":44,"2022":53,"2023":36,"2024":47,"2025":38,"2026":31},"year":2018,"title":"Efficacy and Safety of High-Specific-Activity 131 I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma"},"paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022":{"doi":"10.1007/s00259-022-05727-7","openalexId":"W4221014004","cited":255,"byYear":{"2022":13,"2023":52,"2024":66,"2025":58,"2026":66},"year":2022,"title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands"},"paper-cabinet-cabozantinib-nejm-2024":{"doi":"10.1056/nejmoa2403991","openalexId":"W4402581225","cited":165,"byYear":{"2024":4,"2025":89,"2026":72},"year":2024,"title":"Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors"},"paper-zircon-lancet-oncol-2024":{"doi":"10.1016/s1470-2045(24)00402-9","openalexId":"W4402388619","cited":164,"byYear":{"2023":1,"2024":7,"2025":72,"2026":84},"year":2024,"title":"[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial"},"paper-jadvar-snmmi-psma-auc-jnm-2022":{"doi":"10.2967/jnumed.121.263262","openalexId":"W3203431570","cited":157,"byYear":{"2014":1,"2021":2,"2022":19,"2023":36,"2024":36,"2025":35,"2026":28},"year":2021,"title":"Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging"},"paper-baum-prrt-1048-patients-oncotarget-2018":{"doi":"10.18632/oncotarget.24524","openalexId":"W2790526699","cited":141,"byYear":{"2017":1,"2018":3,"2019":20,"2020":30,"2021":19,"2022":28,"2023":11,"2024":16,"2025":7,"2026":5},"year":2018,"title":"Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms"},"paper-tagawa-ac225-j591-jco-2024":{"doi":"10.1200/jco.23.00573","openalexId":"W4388284228","cited":76,"byYear":{"2020":4,"2021":1,"2022":1,"2024":18,"2025":29,"2026":23},"year":2023,"title":"Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591"}},"missing":[]}